Cat. No.: HY-N0616

Trifolirhizin

Customer Review

Based on 1 Customer Validation

Trifolirhizin is a pterocarpan flavonoid found in the roots of Sophora flavescens. Trifolirhizin is a tyrosinase inhibitor with an IC₅₀ value of 506.77 μM. Trifolirhizin reduces intracellular melanin production and modulates multiple signaling pathways including NFκB-MAPK, AMPK/mTOR, PI3K/Akt, MAPK-NFATc1 and EGFR-MAPK. Trifolirhizin targets biological molecules including PTK6 and COX-2, inhibits the activities of hyaluronidase, collagenase and elastase, induces apoptosis, autophagy and cell cycle arrest, and suppresses the proliferation, migration and invasion of cancer cells. Trifolirhizin exerts diverse pharmacological effects including anti-inflammatory, anti-asthmatic, bone-protective, renoprotective, antibacterial, antifungal, hepatoprotective, antiplatelet, estrogenic and wound-healing activities. Trifolirhizin can be used to investigate a broad range of malignant, inflammatory, metabolic and infectious disorders.

For research use only. We do not sell to patients.

Purity: 98.37%
CAS No.: 6807-83-6
Formula: C₂₂H₂₂O₁₀
Molecular Weight:446.40

Storage:

-20°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Trifolirhizin Chemical Structure

CAS No.: 6807-83-6

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

IC50: 506 μM (tyrosinase)^[1]

All TNF Receptor Isoforms :

All AMPK Isoforms :

All mTOR Isoforms :

All ERK Isoforms :

All NF-κB Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
RAW264.7	IC₅₀	>50 μM Compound: 22	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated nitric oxide production after 24 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated nitric oxide production after 24 hrs by Griess method	[PMID: 26073007]
Vero	EC₅₀	>300 μg/mL Compound: Trifolirhizin	Antiviral activity against HSV1 in african green monkey Vero cells assessed as virus-induced cytopathic effect after 3 days by MTT assay Antiviral activity against HSV1 in african green monkey Vero cells assessed as virus-induced cytopathic effect after 3 days by MTT assay	[PMID: 9868163]

In Vitro

Trifolirhizin exerts anti-inflammatory effects in LPS-stimulated mouse J774A.1 macrophages by downregulating TNF-α, IL-6, and COX-2 expression^[1].
Trifolirhizin (50-100 μg/mL) inhibits wound-healing related enzymes hyaluronidase, collagenase, and elastase, with maximum inhibition observed at 100 μg/mL^[1].
Trifolirhizin (1-500 μg/mL; 12.5-50 μM) exhibits skin-whitening activity by inhibiting tyrosinase (IC₅₀ = 506.77 μM) and reducing melanin production in IBMX-induced B16 melanoma cells (IC₅₀ = 36 μM)^[1].
Trifolirhizin (10-40 μM) inhibits RANKL-induced osteoclast formation and bone resorption in mouse BMMs at 10, 20, and 40 μM by downregulating NFATc1 and osteoclast marker genes^[1].
Trifolirhizin (270-360 μM) inhibits proliferation and induces apoptosis in HL-60 human leukemia cells, while sparing normal lymphocytes at 270-360 μM^[1].
Trifolirhizin (5-250 μM) exerts dose-dependent antiproliferative activity in A2780 human ovarian cancer cells (effective at ≥50 μM) and H23 human lung cancer cells (effective at 250 μM)^[1].
Trifolirhizin (20-40 μg/mL) inhibits proliferation and induces apoptosis in MKN45 human gastric cancer cells (IC₅₀ = 33.27 μg/mL) via cell cycle arrest and modulation of EGFR-MAPK signaling, while exhibiting low toxicity to normal kidney and liver cell lines^[1].
Trifolirhizin induces autophagy-dependent apoptosis in HCT116 and SW620 human colorectal cancer cells by activating the AMPK/mTOR signaling pathway^[1].
Trifolirhizin inhibits proliferation, migration, and invasion of 6-10 B and HK1 human nasopharyngeal carcinoma cells, with IC₅₀ values of 83.67 μmol/L and 33.21 μmol/L at 72 h, by suppressing the PI3K/Akt signaling pathway^[1].
Trifolirhizin (12.5-100 μg/mL; 50.0 μg/mL combined with sorafenib) exhibits dose-dependent antiproliferative activity in MHCC97H, MHCC97L, and HepG2 human hepatocellular carcinoma cells, and synergistically enhances the anticancer effects of sorafenib by inducing apoptosis and modulating cell cycle and signaling pathways^[1].
Trifolirhizin (0.005-2 mg/mL) inhibits proliferation and induces apoptosis in C666-1 human nasopharyngeal carcinoma cells by targeting PTK6 and modulating autophagy-related markers^[1].
Trifolirhizin (100 μg/mL) exhibits antibacterial activity against Helicobacter pylori at 100 μg/mL^[1].
Trifolirhizin (10-25 μM; 2 h pre-incubation, 24 h LPS treatment) dose-dependently inhibits LPS-induced TNF-α and IL-6 mRNA expression in mouse J774A.1 macrophages, with complete inhibition of TNF-α mRNA observed at 25 μM^[2].
Trifolirhizin (10-25 μM) dose-dependently inhibits LPS-induced TNF-α protein production in mouse J774A.1 macrophages, with no significant effect on IL-6 protein production^[2].
Trifolirhizin (100-200 μM; 2 h pre-incubation, 24 h LPS treatment) dose-dependently inhibits LPS-induced COX-2 protein expression in mouse J774A.1 macrophages, with 14% inhibition at 100 μM and 28% inhibition at 200 μM^[2].
Trifolirhizin (0-250 μM; 24 h) dose-dependently inhibits proliferation of human A2780 ovarian cancer cells (with significant 50% growth inhibition at 100 μM) and human H23 lung cancer cells (with significant activity only at 250 μM) after 24 h of incubation^[2].
Trifolirhizin (10-40 μM; 6 h) accelerates autophagy flux in HCT116 and SW620 human colorectal cancer cells, as evidenced by altered autophagy marker protein expression, formation of autophagic vacuoles, and increased autophagosome and autophagolysosome formation^[3].
Trifolirhizin (10-40 μM) activates the AMPK/mTOR signaling pathway in HCT116 and SW620 human colorectal cancer cells, which is essential for its induction of autophagy^[3].
Trifolirhizin (10-45 μM; 48 h) induces caspase-mediated extrinsic pathway apoptosis in HCT116 and SW620 human colorectal cancer cells, reducing cell viability and colony formation^[3].
Trifolirhizin (20 μM)-induced apoptosis in HCT116 and SW620 human colorectal cancer cells is dependent on AMPK activation and autophagy induction, with co-localization of autophagic and apoptotic markers confirming autophagy-mediated cell death^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Real Time qPCR^[2]

Cell Line:

mouse J774A.1 macrophage cells
Concentration:

10-25 μM
Incubation Time:

2 h (pre-incubation); 24 h (LPS treatment)
Result:

Significantly inhibited LPS-induced increases in TNF-α and IL-6 mRNA expression in a dose-dependent manner.
Completely inhibited the LPS-induced increase of TNF-α mRNA levels at 25 μM.

Western Blot Analysis^[2]

Cell Line:

mouse J774A.1 macrophage cells
Concentration:

100-200 μM
Incubation Time:

2 h (pre-incubation); 24 h (LPS treatment)
Result:

Dose-dependently inhibited LPS-stimulated COX-2 protein expression.
Suppressed LPS-induced COX-2 protein production by 14% at 100 μM.
Suppressed LPS-induced COX-2 protein production by 28% at 200 μM, based on the density ratio of COX-2 versus β-actin.

Cell Proliferation Assay^[2]

Cell Line:

human A2780 ovarian cancer cells, human H23 lung cancer cells
Concentration:

0-250 μM
Incubation Time:

24 h
Result:

Dose-dependently suppressed the proliferation of both A2780 ovarian and H23 lung cancer cells.
Showed no antiproliferative activity at concentrations less than 50 μM in either cell line.
Achieved significant 50% growth inhibition in A2780 cells at 100 μM.
Showed significant antiproliferative activity in H23 cells only at 250 μM.

Cell Autophagy Assay^[3]

Cell Line:

HCT116, SW620
Concentration:

10-40 μM (immunoblotting); 20 μM (transmission electron microscopy, Ad-mCherry-GFP-LC3B fluorescent assay)
Incubation Time:

6 h (transmission electron microscopy, Ad-mCherry-GFP-LC3B fluorescent assay)
Result:

Caused dose-related accumulation of LC3B-I and LC3B-II, and increased the LC3B-II/I expression ratio.
Downregulated SQSTM-1 protein expression in both cell lines.
Decreased SQSTM1 content while increased LC3B-II and poly-ubiquitin aggregated in detergent-insoluble fractions.
Revealed autophagic vacuoles (double-membrane compartments with lamellar structures) in treated cells.
Showed increased green (autophagosomes) and red (autophagolysosomes) dots, indicating accelerated autophagy flux.
Impaired trifolirhizin-induced autophagy flux when co-treated with autophagy inhibitors.

Cell Viability Assay^[3]

Cell Line:

HCT116, SW620
Concentration:

10-45 μM (CCK-8 assay); 10-40 μM (immunoblotting assays)
Incubation Time:

48 h (CCK-8 assay)
Result:

Reduced cell viability in a dose-dependent manner.
Inhibited long-term colony formation.
Induced both early and late apoptosis in both cell lines.
Showed unchanged cleaved caspase-9 and cytochrome c expression, but increased cleaved poly ADP-ribose polymerase, cleaved caspase-3, and cleaved caspase-8 expression.
Decreased trifolirhizin's cytotoxicity when co-treated with Z-VAD-FMK.

Parmacokinetics

Species	Dose	Route	AUC_0-t	T_1/2	C_max	MRT	CL
Rat^[1]	20 mg/kg	i.v.	42.0 ng·h/mL	10.6 min	/	8.33 min	22.4 mL/min/kg
Rat^[1]	10 mg/kg	p.o.	552.44 ng·h/mL	0.68 h	1066.83 ng/mL	0.65 h	/

In Vivo

Trifolirhizin (7.5 mg/kg; daily; 5 days prior to carbon tetrachloride exposure and continued for study duration) exerts hepatoprotective effects in carbon tetrachloride-intoxicated Wistar rats by normalizing liver enzyme and bilirubin levels and restoring liver non-protein sulfhydryl groups^[1].
Trifolirhizin (20 mg/kg; single treatment) exhibits strong estrogenic activity in young female Wistar rats, increasing uterine weight by over 90%^[1].
Trifolirhizin (4.5 mg/kg; single treatment) reduces carrageenan-induced hind paw edema in Wistar rats by 35%^[1].
Trifolirhizin (10-20 mg/kg; intraperitoneal injection; daily; 6 weeks) protects against ovariectomy-induced bone loss in female C57BL/6J mice by reducing osteoclast number and bone resorption^[1].
Trifolirhizin (5-10 mg/kg; periosteal injection; days 2, 4, 6, and 8 post-LPS exposure) prevents LPS-induced inflammatory osteolysis in male C57BL/6J mice in vivo in a dose-dependent manner by reducing osteoclast formation and bone destruction^[1].
Trifolirhizin (1-3 mg/kg; daily; 21 days) inhibits gastric tumor growth in BALB/C nude mice, reducing tumor weight and increasing tumor cell apoptosis while decreasing proliferation^[1].
Trifolirhizin (10 mg/kg; once every 3 days; 21 days) suppresses colorectal xenograft tumor growth in C57BL/6 mice by activating the AMPK/mTOR pathway to induce autophagy and caspase-mediated extrinsic apoptosis^[1].
Trifolirhizin (40 mg/kg; every other day; 14 days) inhibits nasopharyngeal carcinoma xenograft tumor growth in male nude mice without causing damage to normal kidney or liver tissue^[1].
Trifolirhizin (12.5-50 mg/kg; intraperitoneal injection; single dose) exerts anti-ulcerative colitis effects in DSS-induced C57BL/6 mice by regulating Th17/Treg balance and suppressing the NLRP3 inflammasome via the AMPK-TXNIP pathway^[1].
Trifolirhizin (12.5-50 mg/kg; daily; 3 weeks) relieves renal injury in male db/db diabetic nephropathy mice by inducing autophagy, inhibiting oxidative stress, and regulating the PI3K/AKT/mTOR pathway^[1].
Trifolirhizin (2-5 mg/kg; daily) mitigates ovalbumin-induced asthma in neonatal Sprague Dawley rats in vivo in a dose-dependent manner by reducing pulmonary inflammation and tissue damage via modulation of the NF-κB pathway^[1].
Trifolirhizin (10 mg/kg) significantly suppresses colorectal cancer xenograft growth in C57BL/6 mice, activates the AMPK/mTOR autophagy pathway, and induces extrinsic apoptosis in tumor cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Wistar rats^[1]
Dosage:

7.5 mg/kg (20.7 μmol/kg)
Administration:

daily; 5 days prior to carbon tetrachloride exposure and continued for study duration
Result:

Significantly reduced serum levels of SGOT, SGPT, ALP, and total bilirubin.
Increased liver non-protein sulfhydryl group levels compared to the carbon tetrachloride-only group.

Animal Model:

C57BL/6J mice (female; ovariectomy-induced bone loss)^[1]
Dosage:

10 mg/kg; 20 mg/kg
Administration:

intraperitoneal injection; daily; 6 weeks
Result:

Reduced ovariectomy-induced bone loss.
Decreased number of TRAP-positive osteoclasts in tibial tissue.
High-dose treatment significantly recovered trabecular bone structure on μCT analysis.

Animal Model:

C57BL/6J mice (male; LPS-induced cranial bone inflammation and bone loss)^[1]
Dosage:

5 mg/kg; 10 mg/kg
Administration:

periosteal injection; days 2, 4, 6, and 8 post-LPS exposure
Result:

Dose-dependently reduced LPS-induced osteolysis.
Increased bone volume/tissue volume (BV/TV).
Decreased bone destruction area.
Reduced number of TRAP-positive osteoclasts and IL-1β-positive area in cranial cap tissue.

Animal Model:

C57BL/6 mice (DSS-induced colitis)^[1]
Dosage:

12.5 mg/kg; 25 mg/kg; 50 mg/kg
Administration:

intraperitoneal injection; single dose
Result:

Dose-dependently reduced disease activity index (DAI).
Increased colon length in 25 and 50 mg/kg groups.
Improved body weight.
Downregulated mRNA and protein expression of TNF-α, IL-6, and IL-1β in colon tissue.
Suppressed p-NF-κB/NF-κB and RORγt protein expression.
Increased Foxp3 expression.
Reduced Th17 (CD4+ IL17+) cells and increased Treg (CD4+ CD25+ Foxp3+) cells in mesenteric lymph nodes and spleen.
Suppressed NLRP3 inflammasome components (NLRP3, caspase 1, ASC).
Regulated the AMPK-TXNIP pathway by reducing p-AMPK/AMPK and increasing TXNIP.

Animal Model:

db/db mice (male; spontaneous type 2 diabetes-induced renal injury)^[1]
Dosage:

12.5 mg/kg; 25 mg/kg; 50 mg/kg
Administration:

daily; 3 weeks
Result:

Reduced body and renal weight.
Decreased fasting blood glucose.
Improved renal histopathology (reduced glomerular hypertrophy, tubular basement membrane thickening, mesangial matrix expansion).
Reduced serum BUN and creatinine.
Suppressed renal tissue apoptosis via TUNEL assay.
Decreased MDA and ROS levels.
Increased SOD levels.
Upregulated LC3II and Beclin1 expression.
Downregulated p62, p-PI3K/PI3K, p-AKT/AKT, and p-mTOR/mTOR expression in renal tissue.

Animal Model:

Sprague Dawley rats (neonatal; ovalbumin-induced pulmonary inflammation and tissue damage)^[1]
Dosage:

2 mg/kg; 4 mg/kg; 5 mg/kg
Administration:

daily
Result:

Dose-dependently reduced serum IgE levels.
Suppressed histological scores (reduced tissue damage, inflammatory cell aggregation, and pulmonary edema).
Downregulated lung Muc5AC and Muc5B gene expression.
Reduced BALF levels of TNF-α, ICAM-1, IL-4, IL-5, and IL-13.
Upregulated lung IκBα protein expression.

Chemical Information

CAS No. 6807-83-6
Appearance Solid
Molecular Weight 446.40
Formula C₂₂H₂₂O₁₀
Color White to off-white
SMILES

O[C@H]([C@@H](O)[C@@H]1O)[C@@H](O[C@@H]1CO)OC2=CC=C3C(OC[C@]4([H])[C@@]3([H])OC5=C4C=C(OCO6)C6=C5)=C2
Structure Classification
- Flavonoids
- Other Flavonoids
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

-20°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (224.01 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.2401 mL

11.2007 mL

22.4014 mL

5 mM

0.4480 mL

2.2401 mL

4.4803 mL

10 mM

0.2240 mL

1.1201 mL

2.2401 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.60 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.60 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.60 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (296 KB)
SDS (597 KB)
- English - EN (597 KB)
- Français - FR (597 KB)
- Deutsch - DE (597 KB)
- Norwegian - NO (597 KB)
- Español - ES (597 KB)
- Swedish - SV (597 KB)
- Italian - IT (597 KB)
- Korean - KR (597 KB)
- Portuguese - PT (597 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Jaiswal V, et al. Trifolirhizin: A Phytochemical with Multiple Pharmacological Properties. Molecules. 2025;30(2):383. Published 2025 Jan 17. [Content Brief]

[2]. Zhou H, et al. Anti-Inflammatory and antiproliferative activities of trifolirhizin, a flavonoid from Sophora flavescens roots. J Agric Food Chem. 2009;57(11):4580-4585. [Content Brief]

[3]. Sun D, et al. Trifolirhizin induces autophagy-dependent apoptosis in colon cancer via AMPK/mTOR signaling. Signal Transduct Target Ther. 2020 Aug 27;5(1):174. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.2401 mL	11.2007 mL	22.4014 mL	56.0036 mL
	5 mM	0.4480 mL	2.2401 mL	4.4803 mL	11.2007 mL
	10 mM	0.2240 mL	1.1201 mL	2.2401 mL	5.6004 mL
	15 mM	0.1493 mL	0.7467 mL	1.4934 mL	3.7336 mL
	20 mM	0.1120 mL	0.5600 mL	1.1201 mL	2.8002 mL
	25 mM	0.0896 mL	0.4480 mL	0.8961 mL	2.2401 mL
	30 mM	0.0747 mL	0.3734 mL	0.7467 mL	1.8668 mL
	40 mM	0.0560 mL	0.2800 mL	0.5600 mL	1.4001 mL
	50 mM	0.0448 mL	0.2240 mL	0.4480 mL	1.1201 mL
	60 mM	0.0373 mL	0.1867 mL	0.3734 mL	0.9334 mL
	80 mM	0.0280 mL	0.1400 mL	0.2800 mL	0.7000 mL
	100 mM	0.0224 mL	0.1120 mL	0.2240 mL	0.5600 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Trifolirhizin

Anti-Infection Compound Library

Apoptosis Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Reprogramming Compound Library

Anti-diabetic Compound Library

Glycoside Compound Library

Lipid Compound Library

Oxygen Sensing Compound Library

Antibacterial Compound Library

Medicine Food Homology Compound Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Flavonoids Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Lipid Metabolism Compound Library

Glucose Metabolism Compound Library

Food-Sourced Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Osteogenesis Compound Library

Cancer Stem Cells Compound Library

Coagulation and Anti-coagulation Compound Library

Pain-Related Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library